Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.29
IRWD's Cash to Debt is ranked lower than
58% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. IRWD: 1.29 )
Ranked among companies with meaningful Cash to Debt only.
IRWD' s 10-Year Cash to Debt Range
Min: 1.1  Med: 95.94 Max: N/A
Current: 1.29
Equity to Asset 0.22
IRWD's Equity to Asset is ranked lower than
92% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IRWD: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
IRWD' s 10-Year Equity to Asset Range
Min: -1.86  Med: 0.45 Max: 0.74
Current: 0.22
-1.86
0.74
F-Score: 5
Z-Score: -0.10
M-Score: 0.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -125.32
IRWD's Operating margin (%) is ranked lower than
90% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. IRWD: -125.32 )
Ranked among companies with meaningful Operating margin (%) only.
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36  Med: -199.39 Max: -48.43
Current: -125.32
-1101.36
-48.43
Net-margin (%) -144.07
IRWD's Net-margin (%) is ranked lower than
91% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. IRWD: -144.07 )
Ranked among companies with meaningful Net-margin (%) only.
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31  Med: -224.96 Max: -48.34
Current: -144.07
-1192.31
-48.34
ROE (%) -147.06
IRWD's ROE (%) is ranked lower than
97% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. IRWD: -147.06 )
Ranked among companies with meaningful ROE (%) only.
IRWD' s 10-Year ROE (%) Range
Min: -299.34  Med: -178.17 Max: -48.14
Current: -147.06
-299.34
-48.14
ROA (%) -40.01
IRWD's ROA (%) is ranked lower than
89% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. IRWD: -40.01 )
Ranked among companies with meaningful ROA (%) only.
IRWD' s 10-Year ROA (%) Range
Min: -107.22  Med: -39.28 Max: -22.85
Current: -40.01
-107.22
-22.85
ROC (Joel Greenblatt) (%) -467.51
IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. IRWD: -467.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -672.27  Med: -258.80 Max: -190.56
Current: -467.51
-672.27
-190.56
Revenue Growth (3Y)(%) -5.30
IRWD's Revenue Growth (3Y)(%) is ranked lower than
80% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IRWD: -5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IRWD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -33.60 Max: -5.3
Current: -5.3
EBITDA Growth (3Y)(%) 27.50
IRWD's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. IRWD: 27.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IRWD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -57.90 Max: 52
Current: 27.5
0
52
EPS Growth (3Y)(%) 28.80
IRWD's EPS Growth (3Y)(%) is ranked higher than
82% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IRWD: 28.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IRWD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -56.40 Max: 54.3
Current: 28.8
0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

IRWD Guru Trades in Q4 2014

Steven Cohen 1,500,100 sh (+16.06%)
Vanguard Health Care Fund 4,166,598 sh (+6.79%)
» More
Q1 2015

IRWD Guru Trades in Q1 2015

Vanguard Health Care Fund 4,231,687 sh (+1.56%)
Steven Cohen 750,000 sh (-50.00%)
» More
Q2 2015

IRWD Guru Trades in Q2 2015

Jim Simons 69,303 sh (New)
Steven Cohen 1,378,600 sh (+83.81%)
Vanguard Health Care Fund 4,367,387 sh (+3.21%)
» More
2015

IRWD Guru Trades in 2015

Steven Cohen 2,005,800 sh (+45.50%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 357.14
IRWD's Forward P/E is ranked lower than
99% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. IRWD: 357.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 11.28
IRWD's P/B is ranked lower than
91% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. IRWD: 11.28 )
Ranked among companies with meaningful P/B only.
IRWD' s 10-Year P/B Range
Min: 5.46  Med: 10.73 Max: 46.91
Current: 11.28
5.46
46.91
P/S 13.92
IRWD's P/S is ranked lower than
88% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. IRWD: 13.92 )
Ranked among companies with meaningful P/S only.
IRWD' s 10-Year P/S Range
Min: 2.65  Med: 21.65 Max: 75.05
Current: 13.92
2.65
75.05
Current Ratio 8.49
IRWD's Current Ratio is ranked higher than
87% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. IRWD: 8.49 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s 10-Year Current Ratio Range
Min: 2.33  Med: 4.41 Max: 9.64
Current: 8.49
2.33
9.64
Quick Ratio 8.49
IRWD's Quick Ratio is ranked higher than
89% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. IRWD: 8.49 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s 10-Year Quick Ratio Range
Min: 2.33  Med: 4.33 Max: 9.04
Current: 8.49
2.33
9.04
Days Inventory 169.48
IRWD's Days Inventory is ranked lower than
74% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. IRWD: 169.48 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s 10-Year Days Inventory Range
Min: 193.31  Med: 730.81 Max: 1266.91
Current: 169.48
193.31
1266.91
Days Sales Outstanding 3.45
IRWD's Days Sales Outstanding is ranked higher than
97% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. IRWD: 3.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s 10-Year Days Sales Outstanding Range
Min: 0.05  Med: 16.14 Max: 889.76
Current: 3.45
0.05
889.76

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 122.78
IRWD's Price/Net Current Asset Value is ranked lower than
98% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. IRWD: 122.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 7.89  Med: 15.00 Max: 228.56
Current: 122.78
7.89
228.56
Price/Tangible Book 11.28
IRWD's Price/Tangible Book is ranked lower than
84% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. IRWD: 11.28 )
Ranked among companies with meaningful Price/Tangible Book only.
IRWD' s 10-Year Price/Tangible Book Range
Min: 5.99  Med: 10.31 Max: 36.28
Current: 11.28
5.99
36.28
Price/Median PS Value 0.65
IRWD's Price/Median PS Value is ranked higher than
88% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. IRWD: 0.65 )
Ranked among companies with meaningful Price/Median PS Value only.
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 0.95 Max: 2.95
Current: 0.65
0.14
2.95
Earnings Yield (Greenblatt) (%) -9.49
IRWD's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. IRWD: -9.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRWD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -10.83  Med: 0.00 Max: 0
Current: -9.49
-10.83
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 151 267 368
EPS($) -0.82 -0.09 0.61
EPS without NRI($) -0.82 -0.09 0.61

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
[email protected] Aug 26 2015 
[email protected] Aug 26 2015 
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals Aug 25 2015 
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
IRONWOOD PHARMACEUTICALS INC Financials Aug 20 2015
10-Q for Ironwood Pharmaceuticals, Inc. Aug 09 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Ironwood's Q2 Loss Wider than Expected, Revenues Miss - Analyst Blog Aug 06 2015
Edited Transcript of IRWD earnings conference call or presentation 5-Aug-15 8:30pm GMT Aug 06 2015
Ironwood Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 05 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2015
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update Aug 05 2015
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with... Aug 05 2015
Q2 2015 Ironwood Pharmaceuticals Inc Earnings Release - After Market Close Aug 05 2015
Ironwood advances drug with potential in 'huge range of diseases' Jul 22 2015
Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973 Jul 22 2015
Ironwood Pharmaceuticals to Host Second Quarter 2015 Investor Update Call Jul 15 2015
Biotech Investors That Own This Name Could See 50 Percent Near Term Upside, After Selloff Jul 10 2015
Ironwood/AstraZeneca to File for Linzess in China in 2016 - Analyst Blog Jul 09 2015
Ironwood eyes China for IBS drug Jul 08 2015
AstraZeneca and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Designed to... Jul 08 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 25 2015
Ironwood Pharmaceuticals Whittled Down Jun 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK